Age, years | | 0.85 | | 0.71 |
< 50 | 252 (82) | | 228 (74) | |
≥ 50 | 191 (82) | | 167 (72) | |
Tumor size (pT) | | 0.29 | | 0.11 |
T1 | 152 (84) | | 140 (77) | |
T2 | 291 (81) | | 255 (71) | |
Tumor location | | 0.52 | | 0.30 |
Medial | 102 (83) | | 90 (73) | |
Central | 107 (86) | | 98 (78) | |
Lateral | 234 (80) | | 207 (71) | |
Histology | | 0.52 | | 0.18 |
Ductal | 354 (82) | | 312 (72) | |
Non-Ductal | 89 (84) | | 83 (78) | |
Histological grade | | 0.35 | | 0.61 |
Grade I | 223 (93) | | 199 (83) | |
Grade II | 42 (80) | | 41 (77) | |
Grade III | 178 (72) | | 155 (63) | |
Number of positive nodes | | < 0.001 | | 0.001 |
None | 303 (87) | | 272 (78) | |
1-3 nodes | 140 (73) | | 123 (64) | |
Positive nodes (%) | | < 0.001 | | < 0.001 |
≤ 20% | 440 (83) | | 393 (74) | |
> 20% | 3 (43) | | 2 (29) | |
Estrogen receptor status | | 0.68 | | 0.80 |
Positive | 161 (79) | | 147 (72) | |
Negative | 146 (80) | | 128 (70) | |
Progesterone receptor status | | 0.26 | | 0.42 |
Positive | 166 (85) | | 146 (75) | |
Negative | 154 (77) | | 138 (69) | |
Preoperation chemotherapy | | 0.28 | | 0.67 |
Yes | 92 (77) | | 88 (74) | |
No | 351 (83) | | 307 (73) | |
Postoperation chemotherapy | | 0.04 | | 0.39 |
Yes | 418 (83) | | 371 (74) | |
No | 25 (69) | | 24 (67) | |
Cycles of postoperation chemotherapy | | 0.056 | | 0.11 |
≤ 4 | 296 (81) | | 262 (72) | |
> 4 | 122 (88) | | 109 (78) | |
Radiotherapy | | 0.46 | | 0.73 |
Yes | 231 (84) | | 204 (74) | |
No | 212 (80) | | 191 (72) | |
Hormonal therapy | | 0.56 | | 0.62 |
Yes | 198 (84) | | 176 (75) | |
No | 245 (80) | | 219 (72) | |